Curriculum Vitae

Judy Nevill
Angelina Medical Research
121 Gaslight Medical Plaza, Suite102
Lufkin, Texas 75904
Email: judy@angelinamedical research.com
Phone: (936)634-0180
Fax: (936)634-3008

Education

Fort Stockton School of Vocational Nursing — Fort Stockton, TX

Medical Experience

2016 – 2017 — **Angelina Medical Research**

- **LVN, Clinical Research Coordinator**

2011 – 2016 — **TAD Clinical Research**

- **LVN, Clinical Research Coordinator**

1998-2004 — **Dr. Kaywin Carter OB/GYN**

- **Responsible for management of back office and staff**
- **Scheduled outpatient and surgical procedures**
- **Responded to patients phone calls and notified patients of results**
- **Set up and assisted Doctor with all office procedures**

1990-1998 — **Dr. James Caskey**

- **Responsible for management of back office**
- **Responded to patients phone calls and notified patients of results**
- **Set up and assisted Doctor with all office procedures**

1986-1990 — **Woodland Heights Medical Center**

- **LVN caring for pre and post-operative patients**



Research Experience

TD-4208-128: A Phase 3, 52 week, Randomized, Active –Controlled Parallel Group Study to Evaluate the Safety and Tolerability of Nebulized TD-4208 in Subjects with COPD

- **Clinical Research Coordinator**

D3251C00004: A Randomized , Double-Blind, Double Dummy, Chronic Dosing (52 week) Placebo-controlled, Parallel Group, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of 3 Doses of Benralizumab (MEDI-563) in Patients with Moderate to Very Severe COPD with a History of COPD Exacerbations (TERRANOVA)

- **Clinical Research Coordinator**
-

PT009003: A Randomized, Double-Blind, Parallel Group, Multicenter Study to Assess the Efficacy and Safety of PT009 compared to PT005 on COPD Exacerbations over a 52 week Treatment Period in Subjects with Moderate to Very Severe COPD

- **Clinical Research Coordinator**

EPOE-11-04: A Phase 3 Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment

- **Clinical Research Coordinator**

EPOE-10-13: A Therapeutic-Equivalence Study Comparing the Efficacy and Safety of Subcutaneous Epoetin Hospira and Epoetin Alfa (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment

- **Clinical Research Coordinator**

H9V-MC-GFRF: A Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY2382770 in Patients With Diabetic Kidney Disease Due to Type 1 or Type 2 Diabetes.

- **Clinical Research Coordinator**

CACZ885M2301: A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP.

- **Clinical Research Coordinator**

CLCZ696B2314: A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality in Patients With Chronic Heart Failure and Reduced Ejection Fraction.

- **Clinical Research Coordinator**

CQVA149A2340: A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB in Patients With COPD Who Have Moderate to Severe Airflow Limitation.

- **Clinical Research Coordinator**

CQVA149A2337: A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.

- **Clinical Research Coordinator**

PT003006-00: A Randomized, Double-Blind (Test Products and Placebo), Chronic Dosing (24 Weeks), Placebo-Controlled, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in

Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg, Open-Label) as an Active Control.

- **Clinical Research Coordinator**

PT003007-00: A Randomized, Double Blind (Test Products and Placebo), Chronic Dosing (24 Weeks), Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo.

- **Clinical Research Coordinator**

PT003008-00: A 28-Week, Multi-Center, Randomized, Double-Blind, Parallel-Group, Active-Controlled Safety Extension Study to Evaluate the Safety and Efficacy of PT003,PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® as an Active Control.

- **Clinical Research Coordinator**

SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma. (AUSTRI)

- **Clinical Research Coordinator**

SAS115358: A 6-month Safety and Benefit Study of Inhaled Fluticasone Propionate/ Salmeterol Combination Versus Inhaled Fluticasone Propionate in the Treatment of 6,200 Pediatric Subjects 4-11 years old With Persistent Asthma.

- **Clinical Research Coordinator**

HZC113782: A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or at risk for cardiovascular disease.

- **Clinical Research Coordinator**